Sulphadoxine/pyrimethamine versus amodiaquine for treating uncomplicated childhood malaria in Gabon: A randomized trial to guide national policy

Malaria Journal

Volumn 7, Issue , 2008, Pages

  Nsimba, Basile ^a   Guiyedi, Vincent ^b   Mabika Mamfoumbi, Modeste ^b   Mourou Mbina, Jean Romain ^b   Ngoungou, Edgard ^b   Bouyou Akotet, Marielle ^b   Loembet, Romaric ^b   Durand, Rémy ^c,d   Le Bras, Jacques ^e,f   Kombila, Maryvonne ^b  

^a Ministry of Health   (Congo)

^b Department of Parasitology Mycology and Tropical Diseases   (Gabon)

^c AVICENNE HOSPITAL   (France)

^d UNIVERSITÉ PARIS 13   (France)

^e BICHAT HOSPITAL   (France)

^f University Paris Descartes   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; ANTIMALARIAL AGENT; MALOXINE; MOLECULAR MARKER; PARACETAMOL; PYRIMETHAMINE PLUS SULPHADOXINE; QUININE; UNCLASSIFIED DRUG; ARTEMISININ DERIVATIVE; ARTESUNATE; DIHYDROPTEROATE SYNTHASE; PYRIMETHAMINE; SESQUITERPENE; SULFADOXINE;

ARTICLE; CHILDHOOD DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GABON; GENE MUTATION; GENOTYPE; HEALTH CARE POLICY; HUMAN; K540E GENE; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; PARASITE ISOLATION; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; RECURRENT INFECTION; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT; VOMITING; WORLD HEALTH ORGANIZATION; ANIMAL; DRUG COMBINATION; DRUG RESISTANCE; ENZYMOLOGY; FOLLOW UP; GENETICS; INFANT; ISOLATION AND PURIFICATION; MUTATION; NEWBORN; PARASITOLOGY; PLASMODIUM FALCIPARUM; TREATMENT OUTCOME;

AMODIAQUINE; ANIMALS; ANTIMALARIALS; ARTEMISININS; CHILD, PRESCHOOL; DIHYDROPTEROATE SYNTHASE; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GABON; HEALTH POLICY; HUMANS; INFANT; INFANT, NEWBORN; MALARIA, FALCIPARUM; MALE; MUTATION; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; PYRIMETHAMINE; SESQUITERPENES; SULFADOXINE; TREATMENT OUTCOME;

EID: 41549132660     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-7-31     Document Type: Article

References (30)

1. Evaluation of efficacy and tolerance of amodiaquine versus chloroquine in the treatment of uncomplicated malaria outbreak in children of Gabon. V Guiyedi J Koko M Bouyou Akotet M Mabika Mamfoumbi PB Matsiegui B Traore M Kombila, Bull Soc Pathol Exot 2001 94 253 257 11681222
2. Amodiaquine remains effective for treating uncomplicated malaria in west and central Africa. P Brasseur R Guiguemde S Diallo V Guiyedi M Kombila P Ringwald P Olliaro, Trans R Soc Trop Med Hyg 1999 93 645 650 10.1016/S0035-9203(99)90083-4 10717757
3. WHO, Assessment of therapeutic efficacy of antimalarial drugs for uncomplicated falciparum malaria in areas with intense transmission Geneva, Switzerland: World Health Organization 2003 WHO/HTM/RBM/2003.50
4. Plasmodium falciparum malaria: resistance to chloroquine, but sensitivity to mefloquine in the Gabon. A prospective in-vitro study. GD Burchard RD Horstmann WH Wernsdorfer M Dietrich, Tropenmed Parasitol 1984 35 1 4 6369691
5. Development of chloroquine resistance in Plasmodium falciparum in Gabon between 1984 and 1987-88 (in vivo evaluation in a school environment). D Richard-Lenoble M Kombila M Martz B Lefevre J Chandenier F Gay X Billiault M Therizol-Ferly, Ann Soc Belg Med Trop 1989 69 113 119 2679451
6. Stability of Plasmodium falciparum resistance to chloroquine between 1987 and 1989 in Mounana, Gabon. D Gueret F Migot P Ringwald P Thibaut J Le Bras, Bull World Health Organ 1992 70 621 624 1464148
7. In vitro sensitivity of Plasmodium falciparum isolates from Gabon to chloroquine and cycloguanil. B Pradines M Mabika Mamfoumbi A Keundjian C Lebeau T Fusai M Owono Medang C Rogier D Parzy M Kombila, Bull Soc Pathol Exot 1999 92 91 94 10399596
8. Chemoresistance of P. falciparum in urban areas of Yaounde, Cameroon. Part 1: Surveillance of in vitro and in vivo resistance of Plasmodium falciparum to chloroquine from 1994 to 1999 in Yaounde, Cameroon. P Ringwald A Same Ekobo A Keundjian D Kedy Mangamba LK Basco, Trop Med Int Health 2000 5 612 619 10.1046/j.1365-3156.2000.00613.x 11044275
9. Surveillance of in vivo resistance of Plasmodium falciparum to antimalarial drugs from 1992 to 1999 in Malabo (Equatorial Guinea). J Roche A Guerra-Neira J Raso A Benito, Am J Trop Med Hyg 2003 68 598 601 12812353
10. Efficacy of sulphadoxine/pyrimethamine in the treatment of uncomplicated Plasmodium falciparum malaria in Republic of Congo. B Nsimba DA Malonga AM Mouata F Louya J Kiori M Malanda D Yocka J Oko-Ossho S Ebata-Mongo J Le Bras, Am J Trop Med Hyg 2004 70 133 138 14993623
11. The public health impact of chloroquine resistance in Africa. JF Trape, Am J Trop Med Hyg 2001 64 12 17 11425173
12. Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomised, multicentre trial. M Adjuik P Agnamey A Babiker S Borrmann P Brasseur M Cisse F Cobelens S Diallo JF Faucher P Garner S Gikunda PG Kremsner S Krishna B Lell M Loolpapit PB Matsiegui MA Missinou J Mwanza F Ntoumi P Olliaro P Osimbo P Rezbach E Some WR Taylor, Lancet 2002 359 1365 1372 10.1016/S0140-6736(02)08348-4 11978332
13. Atovaquone and proguanil versus amodiaquine for the treatment of Plasmodium falciparum malaria in African infants and young children. S Borrmann JF Faucher T Bagaphou MA Missinou RK Binder S Pabisch P Rezbach PB Matsiegui B Lell G Miller PG Kremsner, Clin Infect Dis 2003 37 1441 1447 10.1086/379014 14614665
14. Combination of drug level measurement and parasite genotyping data for improved assessment of amodiaquine and sulfadoxine-pyrimethamine efficacies in treating Plasmodium falciparum malaria in Gabonese children. A Aubouy M Bakary A Keundjian B Mbomat JR Makita F Migot-Nabias M Cot J Le Bras P Deloron, Antimicrob Agents Chemother 2003 47 231 237 12499196 10.1128/AAC.47.1.231-237. 2003
15. Sulfadoxine-pyrimethamine for the treatment of Plasmodium falciparum malaria in Gabonese children. P Deloron J Mayombo A Le Cardinal J Mezui-Me-Ndong C Bruzi-Baert F Lekoulou N Elissa, Trans R Soc Trop Med Hyg 2000 94 188 190 10.1016/S0035-9203(00)90272-4 10897366
16. 5-day nonobserved artesunate monotherapy for treating uncomplicated Falciparum malaria in young Gabonese children. NG Schwarz S Oyakhirome M Potschke B Glaser PK Klouwenberg H Altun AA Adegnika S Issifou JF Kun PG Kremsner MP Grobusch, Am J Trop Med Hyg 2005 73 705 709 16222013
17. Epidemiology of drug-resistant malaria in Republic of Congo: using molecular evidence for monitoring antimalarial drug resistance combined with assessment of antimalarial drug use. B Nsimba S Jafari-Guemouri DA Malonga AM Mouata J Kiori F Louya D Yocka M Malanda R Durand J Le Bras, Trop Med Int Health 2005 10 1030 1037 10.1111/j.1365-3156.2005.01490.x 16185238
18. Malaria in Gabon. 2. Evaluation of the qualitative and quantitative prevalence of parasites in the total school and preschool population of the country. D Richard-Lenoble M Kombila J Chandenier F Gay X Billiault C Nguiri M Martz F Boyer M Bauzou, Bull Soc Pathol Exot 1987 80 3 Pt 2 532 542 3690800
19. WHO, Assessment of therapeutic efficacy of antimalarial drugs for uncomplicated falciparum malaria in areas with intense transmission Geneva, Switzerland: World Health Organization 1996 WHO/MAL/96.1077
20. Pyrimethamine and Proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase : polymerase chain reaction methods for surveillance in Africa. CV Plowe A Djimdé M Bouare OK Doumbo TE Wellems, Am J Trop Med Hyg 1995 52 565 568 7611566
21. Distinguishing recrudescences from new infections in antimalarial clinical trials: major impact of interpretation of genotyping results on estimates of drug efficacy. M Slater M Kiggundu C Dokomajilar MR Kamya N Bakyaita A Talisuna PJ Rosenthal G Dorsey, Am J Trop Med Hyg 2005 73 256 262 16103584
22. Molecular characterisation of airport malaria: four cases in France during summer 1999. S Jafari R Durand D Lusina J Le Bras, Parasite 2002 9 187 191 12116866
23. Some considerations in the design and interpretation of antimalarial drug trials in uncomplicated falciparum malaria. K Stepniewska N White, Malar J 2006 5 127 17187673 10.1186/1475-2875-5-127
24. Molecular epidemiology of malaria in Cameroon. XXI. Baseline therapeutic efficacy of chloroquine, amodiaquine, and sulfadoxine-pyrimethamine monotherapies in children before national drug policy change. LK Basco VF Ngane M Ndounga A Same-Ekobo JC Youmba RT Abodo G Soula, Am J Trop Med Hyg 2006 75 388 395 16968911
25. DHFR and DHPS genotypes of Plasmodium falciparum isolates from Gabon correlate with in vitro activity of pyrimethamine and cycloguanil, but not with sulfadoxine-pyrimethamine treatment efficacy. A Aubouy S Jafari V Huart F Migot-Nabias J Mayombo R Durand M Bakary J Le Bras P Deloron, J Antimicrob Chemother 2003 52 43 49 10.1093/jac/dkg294 12805261
26. Sequence variations in the genes encoding dihydropteroate synthetase and dihydrofolate reductase and clinical response to sulfadoxine-pyrimethamine in patients with acute uncomplicated falciparum malaria. LK Basco R Tahar A Keundjian P Ringwald, J Infect Dis 2000 182 624 628 10.1086/315731 10915101
27. Intensity of malaria transmission and the evolution of drug resistance. IM Hastings WM Watkins, Acta Trop 2005 94 218 229 15847846
28. The impact of age, temperature, and parasite density on treatment outcomes from antimalarial clinical trials in Kampala, Uganda. G Dorsey AF Gasasira R Machekano MR Kamya SG Staedke A Hubbard, Am J Trop Med Hyg 2004 71 531 536 15569778
29. CYP2C8 polymorphism frequencies among malaria patients in Zanzibar. I Cavaco J Strömberg-Nörklit A Kaneko MI Msellem M Dahoma VL Ribeiro A Bjorkman JP Gil, Eur J Clin Pharmacol 2005 61 15 18 10.1007/s00228-004-0871-8 15785959
30. High prevalence of the cytochrome P450 2C8*2 mutation in Northern Ghana. S Röwer U Bienzle A Weise U Lambertz T Forst RN Otchwemah A Pfützner FP Mockenhaupt, Trop Med Int Health 2005 10 1271 1273 16359408